# Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

> **NCT01488890** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 390 (actual)

## Conditions studied

- Dengue
- Dengue Fever
- Dengue Hemorrhagic Fever
- Yellow Fever

## Interventions

- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
- **BIOLOGICAL:** Yellow Fever

## Key facts

- **NCT ID:** NCT01488890
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-06
- **Primary completion:** 2013-09-27
- **Final completion:** 2013-09-27
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01488890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01488890, "Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01488890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*